Basic Parlodel Information

• INN (International Nonproprietary Name): Bromocriptine
• Brand Names Available In United Kingdom: Parlodel; Parlodel Sandoz; Bromocriptin-ratiopharm; Cycloset (US diabetes product)
• ATC Code: G02CB01 (Bromocriptine)
• Forms & Dosages: Tablets 2.5 mg commonly; 5 mg tablets available in some countries (not universal)
• Manufacturers In United Kingdom: Novartis Pharma/Novartis Sandoz; Ratiopharm; Teva; Zentiva; other regional producers
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Rx only (prescription required in nearly all markets)

Latest Research Highlights — UK & EU

Which safety questions are clinicians in the UK and EU watching most closely?

Recent European and UK work since 2022 has focused on comparative safety and metabolic effects of dopamine agonists, with repeated attention on bromocriptine versus newer agents such as cabergoline.

Trials and cohort series consistently show bromocriptine suppresses prolactin effectively but is less well tolerated than cabergoline in many patients.

Research into metabolic outcomes has examined glycaemic control and non‑alcoholic fatty liver disease (MAFLD) endpoints as a niche area where bromocriptine’s dopaminergic and metabolic effects may be beneficial.

Regulatory surveillance from MHRA and EMA continues to highlight orthostatic hypotension and psychiatric adverse events, especially in older patients and during dose escalation.

Public pharmacovigilance data confirm the International Nonproprietary Name as Bromocriptine and that Parlodel is commonly supplied as 2.5 mg tablets in blister packs.

Recent randomised data from Europe report effective prolactin reduction with bromocriptine but higher early discontinuation due to nausea or hypotension when compared with cabergoline.

Small UK cohort studies suggest acceptable long‑term control with bromocriptine for patients who cannot use cabergoline, with patient‑level PROMs showing mixed but improving quality‑of‑life signals in some series.

Regulatory trend monitoring such as MHRA Yellow Card reporting and EU pharmacovigilance counts continue to record hypotension, psychiatric symptoms and gastrointestinal intolerance as leading safety signals.

Clinical Effectiveness In The UK — NHS Outcomes & Patient Reports

What can patients expect if prescribed bromocriptine on the NHS?

NHS prescribing audits show bromocriptine remains effective for hyperprolactinaemia, adjunctive acromegaly therapy and selected Parkinson’s regimens when used with levodopa.

Biochemical control of prolactin is commonly achieved in routine practice, though discontinuation rates are higher than with cabergoline due to nausea and hypotension.

Standard tablets are usually 2.5 mg and typical starting doses for hyperprolactinaemia are 1.25–2.5 mg once or twice daily with maintenance often at or below 7.5 mg per day.

Patients frequently report resumption of menses and fertility improvements after prolactin normalisation, which are important functional outcomes recorded in NHS follow‑up.

Initial intolerance such as nausea and dizziness is common and requires dose titration by a specialist or GP with experience in endocrine therapies.

NHS outcome measurement focuses on biochemical suppression, symptom resolution and monitoring for psychiatric effects in at‑risk patients.

Common Measured Outcomes Include:

• Prolactin normalisation (biochemical response)
• Restoration of menstrual and sexual function
• Reduction in tumour size where relevant
• Reported adverse events leading to discontinuation

NICE and MHRA alignment suggests specialist review for dose escalation and for decisions about switching to or from cabergoline.

Indications & Expanded Uses — MHRA‑Approved And Off‑Label

Why might a clinician choose bromocriptine instead of other dopamine agonists?

MHRA‑aligned indications in the UK mirror wider approvals: hyperprolactinaemia, Parkinson’s disease (adjunct) and acromegaly, with bromocriptine prescribed as a prescription‑only medicine.

The ATC classification is G02CB01 under prolactin inhibitors (ergot derivatives).

Off‑label and research uses seen in UK centres include metabolic syndrome and exploratory work in MAFLD, adjunctive diabetes management (note: Cycloset is licensed in the US only), cluster headache trials and small studies in obsessive‑compulsive disorder.

Off‑label use in the NHS typically proceeds via specialist clinics with documentation of rationale and informed consent.

MHRA‑Approved Indications (Brief Evidence Grade):

• Hyperprolactinaemia — established clinical use with biochemical outcome data (high evidence for prolactin suppression).
• Parkinson’s disease (adjunct) — accepted adjunctive agent, particularly for motor benefit where appropriate (moderate evidence in specialist practice).
• Acromegaly — adjunctive use to reduce GH and IGF‑1 in select patients (moderate evidence as part of multimodal care).

Common Off‑Label Areas (Brief Evidence Grade):

• Metabolic syndrome/MAFLD — exploratory clinical research with emerging but limited human data.
• Cluster headache — small trials and pilot studies without broad approval.
• Adjunctive diabetes therapy (Cycloset) — mechanistically similar compound licensed in the US only.

Conditions Requiring Specialist Referral Before Initiation Include Endocrinology For Tumour Management And Neurology For Parkinsonian Regimens.

Use In Pregnancy And Postpartum Requires Caution; Postpartum Lactation Suppression Is Not A Routine Practice In The UK Without Specialist Indication.

Cabergoline And Quinagolide Are Often Preferred First‑Line For Hyperprolactinaemia When Available And Tolerated.

Composition & Brand Landscape In The UK

What is inside a Parlodel tablet and which brands might a patient see?

The active ingredient is bromocriptine mesilate, with the International Nonproprietary Name Bromocriptine.

Parlodel is the originator brand commonly supplied as 2.5 mg tablets in blister packs.

Generics available in European and EEA markets include Parlodel Sandoz, Bromocriptin‑ratiopharm and generics from suppliers such as Ratiopharm, Teva and Zentiva.

Manufacturers listed in the product information include Novartis Pharma/Novartis Sandoz, Ratiopharm, Teva and Zentiva, among others.

ATC Classification: G02CB01 (prolactin inhibitors; ergot derivatives).

Typical Pack Sizes And Strengths Table:

Pharmacists should check excipients for patients with ergot or excipient sensitivities before dispensing.

Note that Cycloset is a related product licensed in the US for glycaemic control and is not routinely used in UK diabetes care.

Contraindications & Special Precautions — High‑Risk Groups

Who must avoid bromocriptine and who needs extra caution?

Absolute contraindications include uncontrolled hypertension, current or past severe psychotic disorders and known hypersensitivity to bromocriptine or other ergot alkaloids.

Postpartum women with pre‑eclampsia or eclampsia or a high risk of severe cardiovascular disorders should not be given bromocriptine.

Relative precautions include cardiovascular disease (even when controlled), hepatic or renal impairment, history of peptic ulcer disease, prior psychiatric illness and older age due to an increased risk of orthostatic hypotension and CNS effects.

Practical Precautions For Patients:

• Avoid abrupt standing after dosing until tolerance is established.
• Do not drive or operate machinery until the individual response is known and dizziness or drowsiness are absent.
• Avoid alcohol and sedatives where possible as these can worsen hypotension and somnolence.

Monitoring Checkpoints Include Regular Blood Pressure Checks, Psychiatric Review Where Indicated And Clinical Surveillance For Gastrointestinal Intolerance.

Encourage Reporting Of Severe Or Unexpected Events Via The MHRA Yellow Card Scheme.

Dosage Guidelines — NHS‑Aligned Regimens & Adjustments

How is bromocriptine started and adjusted in routine UK care?

Standard adult dosing for hyperprolactinaemia starts at 1.25–2.5 mg once or twice daily, with maintenance commonly up to 7.5 mg per day and a usual maximum of 15 mg per day.

Acromegaly regimens begin similarly and may be titrated up to 20–30 mg per day in specialist practice, while Parkinson’s regimens may reach 10–40 mg per day depending on response.

General Dosing Principles: Start Low And Titrate Slowly To Minimise Nausea And Orthostatic Hypotension.

Missed Dose Advice: Take As Soon As Remembered Unless It Is Near The Time For The Next Dose; Do Not Double Up.

Overdose Signs Include Vomiting, Dizziness, Hypotension, Hallucinations And Cardiac Arrhythmia, And Require Urgent Medical Attention.

Special Populations: Elderly Patients Should Start Lower With Careful BP And CNS Monitoring, And Paediatric Use Is Specialist Only.

Interactions Overview — Foods, Drugs & Yellow Card Signals

Which medications and substances should patients and pharmacists watch for?

Bromocriptine interacts with drugs that affect dopaminergic signalling and agents that influence blood pressure, and may be affected by strong CYP3A4 inhibitors.

Concomitant antipsychotic therapy (dopamine antagonists) can reduce bromocriptine efficacy and potent CYP inhibitors may alter its levels.

Alcohol and sedatives can increase somnolence and orthostatic hypotension risk and should be used cautiously.

MHRA Yellow Card reports most commonly flag hypotension, psychiatric symptoms and gastrointestinal intolerance in real‑world surveillance.

Interaction Checklist (Major / Moderate / Minor):

• Major: Potent CYP3A4 inhibitors and interacting antipsychotics.
• Moderate: Concomitant antihypertensives and sedatives that may worsen hypotension.
• Minor: No specific dietary restrictions, but advise caution with alcohol and excessive caffeine if dizziness occurs.

Pharmacists Should Review Electronic Prescription Records For Interacting Agents And Document Counselling In The Patient Record.

Cultural Perceptions & Patient Habits In The UK

How do UK patients usually learn about and manage treatment with bromocriptine?

Patients in the UK commonly rely on NHS guidance, pharmacist counselling and online patient forums for practical experience and tips for coping with side effects.

Forums such as Patient.info and parenting communities often report success stories about restored fertility and menstrual cycles and also share practical strategies for nausea management.

There is an expectation that pharmacists in Boots, LloydsPharmacy or independent community pharmacies will provide clear, actionable counselling before a patient starts treatment.

Electronic prescriptions and the NHS App help patients order repeats, access medication guidance and report symptoms, which supports adherence and follow‑up.

Common Patient Concerns Include Nausea, Dizziness, Impact On Driving And Fertility.

Typical Advice Sources Are GP, Specialist, Pharmacist And NHS 111.

Regional Supply And Cost Differences Between England, Scotland, Wales And Northern Ireland Affect Decisions About Private Purchase And Formulary Choice.

Practical Tip: Encourage Shared Decision‑Making And Clear Counselling On Dose Titration, Taking With Food And Ways To Reduce Dizziness.

Availability & Pricing Patterns — Pharmacies & NHS Variations

Where can patients obtain Parlodel and what should they expect to pay?

Parlodel and generics are prescription‑only across the UK and are supplied commonly as 2.5 mg tablets in blister packs.

High‑street pharmacies such as Boots and LloydsPharmacy, NHS community pharmacies and regulated online pharmacies dispense bromocriptine on prescription.

Regional prescription charge differences matter: patients in Scotland, Wales and Northern Ireland generally do not pay routine prescription charges, while England operates a per‑item charge with exemptions.

Online pharmacies may offer private purchase options; in our online pharmacy, parlodel is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Occasional stock shortages for older generics occur and local formularies may favour cabergoline, influencing availability of bromocriptine.

Comparable Medicines & Prescribing Preferences

What are the typical alternatives to bromocriptine on an NHS prescription?

Cabergoline and quinagolide are common alternatives, with cabergoline often preferred for its longer half‑life and better tolerability.

Quinagolide is another option for hyperprolactinaemia in some clinics, while pergolide has largely been withdrawn in many markets.

NHS Prescribing Notes: Cabergoline is frequently first‑line for prolactin disorders when tolerated, and bromocriptine is used where rapid action is required, when planning pregnancy in some specialist opinions, or where cost and availability influence choice.

Pros And Cons Checklist:

• Cabergoline — fewer doses per week, often better tolerated, typically costlier than older generics.
• Bromocriptine — shorter half‑life, more frequent dosing, greater early GI and orthostatic side effects but well established in practice.
• Quinagolide — non‑ergot alternative in some settings for hyperprolactinaemia.

Switching Strategy Should Be Undertaken Under Specialist Supervision With Cross‑Titration And Monitoring Of Prolactin Levels And Symptoms.

FAQ — Common NHS Patient Questions

What do patients ask most often about Parlodel and how should a pharmacist answer?

Q: Will Parlodel Affect My Fertility?

A: Many patients regain ovulation and menses after prolactin normalisation; specialist follow‑up is recommended for fertility planning.

Q: Can I Drive While Taking Bromocriptine?

A: Do not drive until you know how the medicine affects you, as orthostatic dizziness is common at initiation.

Q: How Is Bromocriptine Different From Cabergoline?

A: Bromocriptine has a shorter half‑life, requires more frequent dosing and can cause more gastrointestinal and cardiovascular side effects; cabergoline is generally better tolerated.

Q: What Should I Do About Missed Doses?

A: Take the missed dose when remembered unless it is close to the next scheduled dose; do not double the dose.

Technical Definitions:

• Orthostatic Hypotension — a drop in blood pressure on standing that can cause dizziness or fainting.
• Prolactin Normalisation — a reduction of serum prolactin to within the laboratory reference range.

Patients Should Be Reassured That MHRA‑Monitored Risks Are Known And Can Be Reported Via The Yellow Card Scheme.

For Urgent Or Severe Reactions, Contact GP, Specialist Or NHS 111 Immediately.

Guidelines For Proper Use — Pharmacist Counselling & NHS Support

What should pharmacists cover at the counter when dispensing Parlodel?

Counselling should include starting dose and titration schedule, taking with food to reduce nausea, standing slowly to avoid orthostatic hypotension and recognising psychiatric symptoms requiring review.

Storage advice: keep at room temperature, protect from excess moisture and heat, and retain medicine in original blister packaging until use.

Pharmacist Counselling Checklist:

• Confirm indication and review comorbidities and concomitant medicines.
• Explain common adverse effects and practical coping strategies (take with food, split doses if advised).
• Provide written NHS leaflets or links and advise on Yellow Card reporting for serious events.

Document Counselling For Electronic Prescriptions And Flag Any Urgent Referral Needs To The Prescribing Clinician.

Shared Decisions About Alternatives Such As Cabergoline Should Be Discussed When Tolerability Or Availability Is A Concern.

Delivery Across United Kingdom